Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practice

Fong, Chin HengChin HengFongMeti, NicholasNicholasMetiKruser, TimothyTimothyKruserWeiss, JessicaJessicaWeissLiu, Zhihui AmyZhihui AmyLiuTakami, HirokazuHirokazuTakamiNarita, YoshitakaYoshitakaNaritade Moraes, Fabio YnoeFabio Ynoede MoraesDasgupta, ArchyaArchyaDasguptaOng, Choo KhoonChoo KhoonOngCHIH-HSIN YANGJIH-HSIANG LEEKosyak, NatalyaNatalyaKosyakPavlakis, NicholasNicholasPavlakisKongkham, PaulPaulKongkhamDoherty, MarkMarkDohertyLeighl, Natasha BNatasha BLeighlShultz, David BDavid BShultz2023-10-312023-10-312023-08-312072-1439https://scholars.lib.ntu.edu.tw/handle/123456789/636709The role for radiotherapy or surgery in the upfront management of brain metastases (BrM) in epidermal growth factor receptor mutant (EGFRm) or anaplastic lymphoma kinase translocation positive (ALK+) non-small cell lung cancer (NSCLC) is uncertain because of a lack of prospective evidence supporting tyrosine kinase inhibitor (TKI) monotherapy. Further understanding of practice heterogeneity is necessary to guide collaborative efforts in establishing guideline recommendations.enBrain metastases (BrM); anaplastic lymphoma kinase (ALK); epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC)[SDGs]SDG3[SDGs]SDG17Recommended first-line management of asymptomatic brain metastases from EGFR mutant and ALK positive non-small cell lung cancer varies significantly according to specialty: an international survey of clinical practicejournal article10.21037/jtd-22-697376916572-s2.0-85173278585https://api.elsevier.com/content/abstract/scopus_id/85173278585